Inj., tafasitamab-cxix
Products billed under this code include Monjuvi.
Payment limit per 2 MG, by effective quarter, 2Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Monjuvi.
Payment limit per 2 MG, by effective quarter, 2Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Monjuvi | Incyte Corporation | 50881-0013-03 | 100 | $1,442.80 |
| Monjuvi | Incyte Corporation | 73535-0208-01 | 100 | $1,442.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $14.428 | −$0.001 | 2 MG | Inj., tafasitamab-cxix | v1, posted September 17, 2026 |
| 3Q26 | $14.429 | +$0.263 | 2 MG | Inj., tafasitamab-cxix | v1, posted September 15, 2026 |
| 2Q26 | $14.166 | −$0.076 | 2 MG | Inj., tafasitamab-cxix | v1, posted September 15, 2026 |
| 1Q26 | $14.242 | −$0.069 | 2 MG | Inj., tafasitamab-cxix | v1, posted September 15, 2026 |
| 4Q25 | $14.311 | +$0.236 | 2 MG | Inj., tafasitamab-cxix | v1, posted September 8, 2026 |
| 3Q25 | $14.075 | +$0.15 | 2 MG | Inj., tafasitamab-cxix | v1, posted March 10, 2026 |
| 2Q25 | $13.925 | −$0.041 | 2 MG | Inj., tafasitamab-cxix | v1, posted March 10, 2026 |
| 1Q25 | $13.966 | +$0.257 | 2 MG | Inj., tafasitamab-cxix | v1, posted December 19, 2025 |
| 4Q24 | $13.709 | −$0.066 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 11, 2025 |
| 3Q24 | $13.775 | +$0.197 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 11, 2025 |
| 2Q24 | $13.578 | −$0.018 | 2 MG | Inj., tafasitamab-cxix | v1, posted March 11, 2025 |
| 1Q24 | $13.596 | +$0.308 | 2 MG | Inj., tafasitamab-cxix | v1, posted December 19, 2024 |
| 4Q23 | $13.288 | −$0.014 | 2 MG | Inj., tafasitamab-cxix | v1, posted October 10, 2024 |
| 3Q23 | $13.302 | +$0.151 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 5, 2024 |
| 2Q23 | $13.151 | +$0.003 | 2 MG | Inj., tafasitamab-cxix | v1, posted February 23, 2024 |
| 1Q23 | $13.148 | +$0.18 | 2 MG | Inj., tafasitamab-cxix | v1, posted December 6, 2023 |
| 4Q22 | $12.968 | +$0.003 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 22, 2023 |
| 3Q22 | $12.965 | +$0.183 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 9, 2023 |
| 2Q22 | $12.782 | −$0.018 | 2 MG | Inj., tafasitamab-cxix | v1, posted December 14, 2022 |
| 1Q22 | $12.80 | +$0.181 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 8, 2022 |
| 4Q21 | $12.619 | −$0.019 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 2, 2022 |
| 3Q21 | $12.638 | −$0.023 | 2 MG | Inj., tafasitamab-cxix | v1, posted June 2, 2022 |
| 2Q21 | $12.661 | – | 2 MG | Inj., tafasitamab-cxix | v1, posted March 1, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.